X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2112) 2112
fusion proteins, bcr-abl - genetics (1113) 1113
index medicus (995) 995
animals (885) 885
chronic myelogenous leukemia (875) 875
hematology (872) 872
chronic myeloid-leukemia (738) 738
leukemia, myelogenous, chronic, bcr-abl positive - genetics (699) 699
mice (694) 694
fusion proteins, bcr-abl - metabolism (691) 691
biochemistry & molecular biology (622) 622
bcr-abl (620) 620
imatinib mesylate (618) 618
oncology (553) 553
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (518) 518
hemic and lymphatic diseases (482) 482
benzamides (480) 480
leukemia (477) 477
leukemia, myelogenous, chronic, bcr-abl positive - pathology (464) 464
male (460) 460
female (431) 431
cell biology (420) 420
pyrimidines - pharmacology (389) 389
fusion proteins, bcr-abl - antagonists & inhibitors (374) 374
chronic myeloid leukemia (363) 363
phosphorylation (362) 362
philadelphia-chromosome (358) 358
mutation (352) 352
adult (345) 345
imatinib (341) 341
apoptosis (332) 332
piperazines - pharmacology (330) 330
antineoplastic agents - pharmacology (325) 325
k562 cells (324) 324
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (321) 321
cell line, tumor (320) 320
cancer (315) 315
tyrosine kinase (315) 315
middle aged (311) 311
molecular sequence data (302) 302
protein kinase inhibitors - pharmacology (289) 289
base sequence (279) 279
research (278) 278
signal transduction (277) 277
tumor cells, cultured (271) 271
cell line (258) 258
fusion proteins, bcr-abl - chemistry (233) 233
pyrimidines - therapeutic use (231) 231
acute lymphoblastic-leukemia (229) 229
proteins (229) 229
apoptosis - drug effects (228) 228
cml (226) 226
antineoplastic agents - therapeutic use (223) 223
genetic aspects (220) 220
aged (209) 209
genetics & heredity (209) 209
piperazines - therapeutic use (205) 205
protein-tyrosine kinases - antagonists & inhibitors (205) 205
kinases (193) 193
transfection (191) 191
abridged index medicus (190) 190
fusion protein (190) 190
cells (186) 186
drug resistance, neoplasm (184) 184
expression (180) 180
polymerase chain reaction (180) 180
tyrosine (178) 178
protein kinase inhibitors - therapeutic use (174) 174
gene expression (173) 173
protein-tyrosine kinases - metabolism (170) 170
oncogene proteins, fusion - genetics (167) 167
fusion proteins, bcr-abl - physiology (165) 165
gene (165) 165
rna, messenger - genetics (164) 164
c-abl (163) 163
resistance (162) 162
drug resistance, neoplasm - genetics (159) 159
activation (158) 158
reverse transcriptase polymerase chain reaction (158) 158
bcr protein (157) 157
neoplasms (156) 156
philadelphia chromosome (155) 155
research article (154) 154
amino acid sequence (152) 152
fusion proteins, bcr-abl (150) 150
multidisciplinary sciences (149) 149
dasatinib (144) 144
abl protein (142) 142
article (141) 141
protein (137) 137
cell proliferation - drug effects (136) 136
protein structure, tertiary (135) 135
protein-tyrosine kinases - genetics (135) 135
adolescent (134) 134
translocation, genetic (134) 134
leukemia, myelogenous, chronic, bcr-abl positive - therapy (133) 133
therapy (132) 132
analysis (131) 131
protein binding (131) 131
precursor cell lymphoblastic leukemia-lymphoma - genetics (128) 128
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2478) 2478
Japanese (10) 10
Chinese (5) 5
German (2) 2
Polish (2) 2
Spanish (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Journal Article
Cell, ISSN 0092-8674, 10/2011, Volume 147, Issue 2, pp. 306 - 319
Journal Article
Nature, ISSN 0028-0836, 01/2010, Volume 463, Issue 7280, pp. 501 - 506
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of... 
CELL LUNG-CANCER | KINASE-INHIBITOR | SELECTIVE INHIBITOR | C-ABL | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | DYNAMICS | MUTATIONS | LYMPHOBLASTIC-LEUKEMIA | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Transplantation, Heterologous | Piperazines - chemistry | Pyrimidines - chemistry | Pyrimidines - metabolism | Antineoplastic Agents - metabolism | Mass Spectrometry | Bone Marrow Transplantation | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Binding Sites | Disease Models, Animal | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Crystallization | Antineoplastic Combined Chemotherapy Protocols | Models, Molecular | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Mutation - genetics | Imatinib Mesylate | Piperazines - pharmacology | Fusion Proteins, bcr-abl - genetics | Animals | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Nilotinib | Dasatinib | Drug resistance in microorganisms | Usage | Nuclear magnetic resonance spectroscopy | Research | Chronic myeloid leukemia | X-ray crystallography | Chromosome abnormalities | Gene mutations | Analysis | Genetic aspects | Diagnosis | Binding proteins | Drug therapy | Health aspects | Proteins | Studies | Competition | Enzymes | E coli | Kinases | Drug resistance | Crystal structure | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 9, pp. 1634 - 1648
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 9/2013, Volume 110, Issue 37, pp. 14924 - 14929
The dysregulated ty rosi ne kinase BCR-ABL causes chronic myelogenous leukemia in humans and forms a large multiprotein complex that includes the Src-homology... 
Proteins | Phosphorylation | Phosphatases | HEK293 cells | Leukemia | Cell lines | Libraries | Chronic myeloid leukemia | Scaffolds | Crystal structure | Engineered proteins | Tyrosine phosphatase | Interaction proteomics | Protein interaction inhibitor | CELLS | ACTIVATION | MULTIDISCIPLINARY SCIENCES | engineered proteins | BINDING-PROTEINS | CHRONIC MYELOID-LEUKEMIA | tyrosine phosphatase | ROLES | MYELOGENOUS LEUKEMIA | protein interaction inhibitor | FACTOR RECEPTOR-BETA | GROWTH-FACTOR | interaction proteomics | PROTEIN-TYROSINE-PHOSPHATASE | PHOSPHOTYROSINE PHOSPHATASE | Fusion Proteins, bcr-abl - chemistry | Amino Acid Sequence | Peptides - chemistry | Signal Transduction | Humans | Enzyme Inhibitors - pharmacology | Peptides - genetics | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Models, Molecular | Crystallography, X-Ray | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - chemistry | Peptide Library | Peptides - pharmacology | src Homology Domains | Fusion Proteins, bcr-abl - genetics | Cell Transformation, Neoplastic | Enzyme Inhibitors - chemistry | Fusion Proteins, bcr-abl - antagonists & inhibitors | HEK293 Cells | K562 Cells | Protein Binding | Protein Interaction Domains and Motifs | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics | Adaptor Proteins, Signal Transducing - metabolism | Tyrosine | Physiological aspects | Homology (Biology) | Research | Health aspects | Phosphotransferases | Biological Sciences
Journal Article